Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash from Operations: 2016-2021

Historic Cash from Operations for ENDRA Life Sciences (NDRA) over the last 6 years, with Dec 2021 value amounting to -$2.7 million.

  • ENDRA Life Sciences' Cash from Operations fell 27.96% to -$2.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$11.1 million, marking a year-over-year decrease of 3.50%. This contributed to the annual value of -$7.4 million for FY2024, which is 22.50% up from last year.
  • Per ENDRA Life Sciences' latest filing, its Cash from Operations stood at -$2.7 million for Q4 2021, which was up 3.42% from -$2.7 million recorded in Q3 2021.
  • ENDRA Life Sciences' 5-year Cash from Operations high stood at -$236,274 for Q1 2017, and its period low was -$3.5 million during Q2 2020.
  • Its 3-year average for Cash from Operations is -$2.5 million, with a median of -$2.6 million in 2019.
  • As far as peak fluctuations go, ENDRA Life Sciences' Cash from Operations plummeted by 937.73% in 2018, and later grew by 18.90% in 2021.
  • Over the past 5 years, ENDRA Life Sciences' Cash from Operations (Quarterly) stood at -$1.4 million in 2017, then slumped by 38.30% to -$1.9 million in 2018, then declined by 0.27% to -$1.9 million in 2019, then declined by 8.68% to -$2.1 million in 2020, then declined by 27.96% to -$2.7 million in 2021.
  • Its Cash from Operations stands at -$2.7 million for Q4 2021, versus -$2.7 million for Q3 2021 and -$2.8 million for Q2 2021.